Form 8-K - Current report:
SEC Accession No. 0001213900-24-071489
Filing Date
2024-08-21
Accepted
2024-08-21 16:44:14
Documents
14
Period of Report
2024-08-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0211899-8k_aditxt.htm   iXBRL 8-K 41632
2 THIRD AMENDING AGREEMENT BETWEEN APPILI THERAPEUTICS, INC., ADITXT, INC. AND ADI ea021189901ex2-1_aditxt.htm EX-2.1 69390
  Complete submission text file 0001213900-24-071489.txt   304406

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE adtx-20240820.xsd EX-101.SCH 3009
4 XBRL LABEL FILE adtx-20240820_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE adtx-20240820_pre.xml EX-101.PRE 22355
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0211899-8k_aditxt_htm.xml XML 3784
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39336 | Film No.: 241229234
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)